Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Completed · Phase 2

Conditions studied: Acne Vulgaris

In brief

Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris

Key facts

Study ID

NCT02938494

Run by

Bausch Health Americas, Inc.

People needed

210

Starts

2015-11-01

Expected to finish

2016-09-01

Last updated by the study team

2020-09-23

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Valeant Site 03 — Encinitas, California, United States
• Valeant Site 04 — Fremont, California, United States
• Valeant Site 06 — Los Angeles, California, United States
• Valeant Site 14 — Sacramento, California, United States
• Valeant Site 01 — Santa Monica, California, United States
• Valeant Site 05 — Colorado Springs, Colorado, United States
• Valeant Site 08 — Coral Gables, Florida, United States
• Valeant Site 10 — Miami, Florida, United States
• Valeant Site 09 — Miramar, Florida, United States
• Valeant Site 12 — Louisville, Kentucky, United States
• Valeant Site 13 — Louisville, Kentucky, United States
• Valeant Site 02 — Rockville, Maryland, United States
• Valeant Site 07 — Fridley, Minnesota, United States
• Valeant Site 16 — Chapel Hill, North Carolina, United States
• Valeant Site 15 — High Point, North Carolina, United States
• Valeant Site 11 — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.